Get started
Author

Shruthi Prasad

Observed names: Prasad, Shruthi, S. Prasad
Observed institutions: University of Freiburg, German Cancer Research Center, University Medical Center Freiburg, Essen University Hospital, Deutsches Konsortium für Translationale Krebsforschung, University of Duisburg-Essen
ORCID: 0000-0003-1787-548X
Observed ORCID: 0000-0003-1787-548X
OpenAlex ID: A5087243861
Patient-derived glioblastoma stem cells are killed by CD133-specific CAR T cells but induce the T cell aging marker CD57
2014 · Xuekai Zhu, Shruthi Prasad, et al. · Oncotarget · 159
PDF
Noninvasive positron emission tomography and fluorescence imaging of CD133 + tumor stem cells
2014 · Simone Gaedicke, Friederike Braun, et al. · Proceedings of the National Academy of Sciences · 98
Checkpoint Antibodies but not T Cell–Recruiting Diabodies Effectively Synergize with TIL-Inducing γ-Irradiation
2016 · Michael Hettich, Jayashree Lahoti, et al. · Cancer Research · 79
PDF
Restoration of T-cell Effector Function, Depletion of Tregs, and Direct Killing of Tumor Cells: The Multiple Mechanisms of Action of a-TIGIT Antagonist Antibodies
2020 · Julie Preillon, Julia Cuende, et al. · Molecular Cancer Therapeutics · 67
PDF
Tumor-associated hematopoietic stem and progenitor cells positively linked to glioblastoma progression
2021 · I-Na Lu, Celia Dobersalske, et al. · Nature Communications · 55
PDF
Effective Eradication of Glioblastoma Stem Cells by Local Application of an AC133/CD133-Specific T-cell–Engaging Antibody and CD8 T Cells
2015 · Shruthi Prasad, Simone Gaedicke, et al. · Cancer Research · 41
Abstract LB-291: EOS100850, an insurmountable and non-brain penetrant A2A receptor antagonist, inhibits adenosine-mediated T cell suppression, demonstrates anti-tumor activity and exhibits best-in class characteristics
2018 · Erica Houthuys, Reece Marillier, et al. · Cancer Research · 10
A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
2022 · Sied Kebir, Vivien Ullrich, et al. · Clinical Cancer Research · 7
PDF
Abstract LB-114: a-TIGIT antagonist antibody EOS884448 shows dual mechanism of action by restoration of T cell effector functions and preferential depletion of Treg
2018 · XAVIER LEROY, Catherine Hoofd, et al. · Cancer Research · 6
Abstract 3278: EOS100850 potently restores adenosine A2Areceptor-dependent suppression of T cell function in the adenosine rich tumor microenvironment
2019 · Erica Houthuys, Paola Basilico, et al. · Cancer Research · 1
Supplementary Tables S1-4 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
2025 · Sied Kebir, Vivien Ullrich, et al.
Supplementary Figure S1 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
2025 · Sied Kebir, Vivien Ullrich, et al.
Supplementary Figure S3 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
2025 · Sied Kebir, Vivien Ullrich, et al.
Supplementary Figure S2 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
2025 · Sied Kebir, Vivien Ullrich, et al.
Supplementary Figure S4 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
2025 · Sied Kebir, Vivien Ullrich, et al.
Supp Figures from Restoration of T-cell Effector Function, Depletion of Tregs, and Direct Killing of Tumor Cells: The Multiple Mechanisms of Action of a-TIGIT Antagonist Antibodies
2023 · Julie Preillon, Julia Cuende, et al.
Supplementary Data from Restoration of T-cell Effector Function, Depletion of Tregs, and Direct Killing of Tumor Cells: The Multiple Mechanisms of Action of a-TIGIT Antagonist Antibodies
2023 · Julie Preillon, Julia Cuende, et al.
Supp Figures from Restoration of T-cell Effector Function, Depletion of Tregs, and Direct Killing of Tumor Cells: The Multiple Mechanisms of Action of a-TIGIT Antagonist Antibodies
2023 · Julie Preillon, Julia Cuende, et al.
Data from Restoration of T-cell Effector Function, Depletion of Tregs, and Direct Killing of Tumor Cells: The Multiple Mechanisms of Action of a-TIGIT Antagonist Antibodies
2023 · Julie Preillon, Julia Cuende, et al.
Data from Restoration of T-cell Effector Function, Depletion of Tregs, and Direct Killing of Tumor Cells: The Multiple Mechanisms of Action of a-TIGIT Antagonist Antibodies
2023 · Julie Preillon, Julia Cuende, et al.
Supplementary Tables S1-4 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
2023 · Sied Kebir, Vivien Ullrich, et al.
Supplementary Figure S4 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
2023 · Sied Kebir, Vivien Ullrich, et al.
Supplementary Figure S1 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
2023 · Sied Kebir, Vivien Ullrich, et al.
Supplementary Figure S2 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
2023 · Sied Kebir, Vivien Ullrich, et al.
Supplementary Figure S3 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
2023 · Sied Kebir, Vivien Ullrich, et al.
Works count: 44
Citation count: 523
H-index: 7
I10-index: 7
Year
Topic
Type